Applying complement therapeutics to rare diseases
Edimara S Reis, Dimitrios C Mastellos, Despina Yancopoulou, Antonio M Risitano, Daniel Ricklin, John D Lambris, Edimara S Reis, Dimitrios C Mastellos, Despina Yancopoulou, Antonio M Risitano, Daniel Ricklin, John D Lambris
Abstract
Around 350 million people worldwide suffer from rare diseases. These may have a genetic, infectious, or autoimmune basis, and several include an inflammatory component. Launching of effective treatments can be very challenging when there is a low disease prevalence and limited scientific insights into the disease mechanisms. As a key trigger of inflammatory processes, complement has been associated with a variety of diseases and has become an attractive therapeutic target for conditions involving inflammation. In view of the clinical experience acquired with drugs licensed for the treatment of rare diseases such as hereditary angioedema and paroxysmal nocturnal hemoglobinuria, growing evidence supports the safety and efficacy of complement therapeutics in restoring immune balance and preventing aggravation of clinical outcomes. This review provides an overview of the candidates currently in the pharmaceutical pipeline with potential to treat orphan diseases and discusses the molecular mechanisms triggered by complement involved with the disease pathogenesis.
Keywords: Autoimmune diseases; C1 inhibitor; Complement; Compstatin; Eculizumab; Orphan drugs; Rare diseases.
Conflict of interest statement
Declaration of Interest
JD Lambris and D Ricklin are inventors of patent applications that describe the use of complement inhibitors for therapeutic purposes. JD Lambris is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors. AM Risitano received research funding from Alexion Pharmaceuticals, Amyndas Pharmaceuticals, Alnylam Pharmaceuticals, Rapharma and Novartis and is a consultant for Alnylam and RA Pharma. The other authors declare no financial interest or conflict.
Copyright © 2015 Elsevier Inc. All rights reserved.
Figures
Source: PubMed